In conclusion, our study revealed that acute intravenous injection of humanized an-ti-HMGB1 mAb produced a beneficial effect through the inhibition of the inflammatory responses, facilitation of the resolution of hematoma, and suppression of iron deposition after ICH. This evidence concerns the gene HMGB1 and hematoma.